Document:

EX-4.6

 Exhibit 4.6 

DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO 

SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 

The paragraphs below describe the units, common stock, and public warrants of Vincerx Pharma, Inc. (the “Company”). The following
summary of the material terms of our securities is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our Second Amended and Restated Certificate of Incorporation
(“Certificate of Incorporation”), our Amended and Restated Bylaws (“Bylaws”) and the warrant-related documents described herein. We urge to you reach each of our Certificate of Incorporation, our Bylaws and the warrant-related
documents described herein in their entirety for a complete description of the rights and preferences of our securities. 
 Our Certificate
of Incorporation authorizes the issuance of 120,000,000 shares of common stock, $0.0001 par value per share and 30,000,000 shares of undesignated preferred stock, $0.0001 par value per share. As of December 31, 2020, there were 13,984,441
shares of common stock (which include 2,744,586 shares of common stock constituting part of the units) and no shares of preferred stock outstanding. The outstanding shares of common stock are duly authorized, validly issued, fully paid and non-assessable. 
 Units 

Each unit consists of one share of common stock and one public warrant. Each public warrant entitles the holder thereof to purchase one-half of a share common stock at a price of $11.50 per whole share of common stock, subject to adjustment as discussed below. 

Common Stock 
 Voting Power 

Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock and subject to
that certain Voting and Support Agreement, dated December 23, 2020, by and among the Company, the founding stockholders listed on Schedule A thereto, and the investors listed in Schedule B thereto (the “Voting Agreement”), the holders
of common stock possess all voting power for the election of our directors and all other matters requiring stockholder action. Holders of common stock are entitled to one vote per share on matters to be voted on by stockholders. 

Dividends 
 Holders of common stock
will be entitled to receive such dividends, if any, as may be declared from time to time by our board of directors in its discretion out of funds legally available therefor. 

Liquidation, Dissolution and Winding Up 

In the event of our voluntary or involuntary liquidation, dissolution, distribution of assets
or winding-up, the holders of the common stock will be entitled to receive an equal amount per share of all of our assets of whatever kind available for distribution to stockholders, after the rights
of the holders of the preferred stock have been satisfied. 
 Preemptive or Other Rights 

Our stockholders have no preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to common
stock. 
 Election of Directors 

Our board of directors is divided into three classes, each of which will generally serve for a term of three years with only one class of
directors being elected in each year. There is no cumulative voting with respect to the election of directors, with the result that the holders of more than 50% of the shares voted for the election of directors can elect all of the directors. 

  
 1 

 Pursuant to the Voting Agreement, our board of directors consists of nine members, with
certain stockholders of the Company having the right to designate seven members, and LifeSci Investments, LLC, LifeSci Holdings LLC, Rosedale Park, LLC and certain other parties to the Voting Agreement having the right to designate two members. 

Warrants 
 Each public warrant entitles
the registered holder to purchase one-half (1/2) of a share of common stock at a price of $11.50 per whole share of common stock, subject to adjustment as discussed below, at any time commencing on
the later of one year after the closing of the initial public offering of LifeSci Acquisition Corp., our predecessor company, or the consummation of a business combination. Pursuant to the Warrant Agreement, dated March 5, 2020, with
Continental Stock Transfer & Trust Company (the “Warrant Agreement”), a warrantholder may exercise its warrants only for a whole number of shares. This means that only an even number of public warrants may be exercised at any
given time by a warrantholder. However, no warrant will be exercisable for cash unless we have an effective and current registration statement, covering our common stock issuable upon exercise of warrants and a current prospectus relating to such
common stock. The warrants will expire at 5:00 p.m., New York City time, on December 23, 2025 (five years from the closing of our initial business combination). 

We may call the outstanding warrants for redemption, in whole and not in part, at a price of $.01 per warrant: 

 

	 	•	 	 at any time while the warrants are exercisable, 

 

	 	•	 	 upon not less than 30 days’ prior written notice of redemption to each warrant holder,

  

	 	•	 	 if, and only if, the reported last sale price of our common stock equals or exceeds $16.50 per share,

  

	 	•	 	 for any 20 trading days within a 30-day trading period ending
on the third business day prior to the notice of redemption to warrant holders, and 

  

	 	•	 	 if, and only if, there is a current registration statement in effect with respect to the shares of common stock
underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption. 

The right to exercise will be forfeited unless the warrants are exercised prior to the date specified in the notice of redemption. On and
after the redemption date, a record holder of a warrant will have no further rights except to receive the redemption price for such holder’s warrant upon surrender of such warrant. 

The redemption criteria for warrants have been established at a price which is intended to provide warrant holders a reasonable premium to the
initial exercise price and provide a sufficient differential between the then-prevailing share price and the warrant exercise price so that if our common stock price declines as a result of our redemption call, the redemption will not cause the
stock price to drop below the exercise price of the warrants. 
 If we call the warrants for redemption as described above, our management
will have the option to require all holders that wish to exercise warrants to do so on a “cashless basis.” In such event, each holder would pay the exercise price by surrendering the warrants for that number of shares of common stock equal
to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined below),
by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of our common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is
sent to the holders of warrants. Whether we will exercise our option to require all holders to exercise warrants on a “cashless basis” will depend on a variety of factors including the price of common stock at the time the warrants are
called for redemption, its cash needs at such time and concerns regarding dilutive share issuances. 
 The public warrants were issued in
registered form pursuant to the Warrant Agreement. The Warrant Agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval, by
written consent or vote, of the holders of a majority of the then outstanding warrants in order to make any change that adversely affects the interests of the registered holders. 

  
 2 

 The exercise price and number of shares of common stock issuable on exercise of the warrants
may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuances of common stock at a
price below their respective exercise prices. 
 The warrants may be exercised upon surrender of the warrant certificate on or prior to the
expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price, by certified or official bank check
payable to us, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of shares of common stock and any voting rights until they exercise their warrants and receive shares of common stock.
After the issuance of common stock upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders. 

Except as described above, no warrant will be exercisable for cash and we will not be obligated to issue shares of our common stock unless at
the time a holder seeks to exercise such warrant, a prospectus relating to the shares of common stock issuable upon exercise of the warrants is current and the shares of common stock have been registered or qualified or deemed to be exempt under the
securities laws of the state of residence of the holder of the warrants. Under the terms of the Warrant Agreement, we have agreed to use our best efforts to meet these conditions and to maintain a current prospectus relating to the shares of common
stock issuable upon exercise of the warrants until the expiration of the warrants. However, we cannot assure you that we will be able to do so and, if we do not maintain a current prospectus relating to the shares of common stock issuable upon
exercise of the warrants, holders will be unable to exercise their warrants and we will not be required to settle any such warrant exercise. If the prospectus relating to the shares of common stock issuable upon the exercise of the warrants is not
current or if the shares of common stock are not qualified or exempt from qualification in the jurisdictions in which the holders of the warrants reside, we will not be required to net cash settle or cash settle the warrant exercise, the warrants
may have no value, the market for the warrants may be limited and the warrants may expire worthless. 
 Warrant holders may elect to be
subject to a restriction on the exercise of their warrants such that an electing warrant holder would not be able to exercise their warrants to the extent that, after giving effect to such exercise, such holder would beneficially own in excess of
9.9% of our outstanding common stock. 
 No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the
warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round down to the nearest whole number of shares of common stock to be issued to the warrant holder. 

Certain Anti-Takeover Provisions of Delaware Law 

Special Meetings of Stockholders 

Our Bylaws provide that special meetings of our stockholders may be called only by a majority vote of our board of directors or our Secretary,
at the request of our Chairman or the Chief Executive Officer. 
 Advance Notice Requirements for Stockholder Proposals and Director Nominations

 Pursuant to Rule 14a-8 of the Exchange Act, proposals seeking inclusion in
our annual proxy statement must comply with the notice periods contained therein. To be timely under our Bylaws, a stockholder’s notice will need to be received by the Company secretary at our principal executive offices not later than the
close of business on the 90th day nor earlier than the open of business on the 120th day prior the anniversary of the date of our proxy statement provided in connection with the previous year’s annual meeting of stockholders. Our
Bylaws specify certain requirements as to the form and content of a stockholders’ meeting. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors
at our annual meeting of stockholders. 

  
 3 

 Authorized but Unissued Shares 

Our authorized but unissued common stock and preferred stock are available for future issuances without stockholder approval and could be
utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could render more
difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise. 
 Exclusive Forum
Selection 
 Our Certificate of Incorporation requires, to the fullest extent permitted by law, that derivative actions brought in
our name, actions against directors, officers and employees for breach of fiduciary duty and other similar actions may be brought in the Court of Chancery in the State of Delaware or, if that court lacks subject matter jurisdiction, another federal
or state court situated in the State of Delaware. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provisions in our Certificate of
Incorporation. Our Certificate of Incorporation also requires the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action under the Securities Act of 1933, as amended
(the “Securities Act”) and the Exchange Act, and the stockholder bringing the suit will be deemed to have to service of process on such stockholder’s counsel. Although we believe these provisions benefit us by providing increased
consistency in the application of Delaware law in the types of lawsuits to which it applies, a court may determine that these provisions are unenforceable, and to the extent they are enforceable, the provisions may have the effect of discouraging
lawsuits against our directors and officers, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. 

Section 203 of the Delaware General Corporation Law 

We are subject to the provisions of Section 203 of the Delaware General Corporation Law (the “DGCL”) regulating corporate
takeovers. In general, Section 203 prohibits a publicly-held Delaware corporation from engaging, under certain circumstances, in a business combination with an interested stockholder for a period of three years following the date the person
became an interested stockholder unless: 
  

	 	•	 	 prior to the date of the transaction, the board of directors of the corporation approved either the business
combination or the transaction which resulted in the stockholder becoming an interested stockholder; 

  

	 	•	 	 upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the
interested stockholder, (1) shares owned by persons who are directors and also officers and (2) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held
subject to the plan will be tendered in a tender or exchange offer; or at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting
of stockholders, and not by written consent, by the affirmative vote of at least 662/3% of the outstanding voting stock which is not owned by the interested stockholder. 

Generally, a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to
the “interested stockholder” and an “interested stockholder” is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more
of a corporation’s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that Section 203 may
discourage business combinations or other attempts that might result in a premium over the market price for the shares of common stock held by our stockholders. The provisions of DGCL, our Certificate of Incorporation and our Bylaws could have the
effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These
provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. 

  
 4 

 Limitation on Liability and Indemnification of Directors and Officers 

Our Certificate of Incorporation limits our directors’ liability to the fullest extent permitted under the DGCL. The DGCL provides that
directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except for liability: 
  

	 	•	 	 for any transaction from which the director derives an improper personal benefit; 

 

	 	•	 	 for any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

  

	 	•	 	 for any unlawful payment of dividends or redemption of shares; or 

 

	 	•	 	 for any breach of a director’s duty of loyalty to the corporation or its stockholders.

 If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of
directors, then the liability of our directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. 

Delaware law and our Certificate of Incorporation provide that we will, in certain situations, indemnify its directors and officers and may
indemnify other employees and other agents, to the fullest extent permitted by law. Any indemnified person is also entitled, subject to certain limitations, to advancement, direct payment, or reimbursement of reasonable expenses (including
attorneys’ fees and disbursements) in advance of the final disposition of the proceeding. 
 In addition, we have entered into separate
indemnification agreements with its directors and officers. These agreements, among other things, require us to indemnify our directors and officers for certain expenses, including attorneys’ fees, judgments, fines, and settlement amounts
incurred by a director or officer in any action or proceeding arising out of their services as one of our directors or officers or any other company or enterprise to which the person provides services at our request. 

We plan to maintain a directors’ and officers’ insurance policy pursuant to which our directors and officers are insured against
liability for actions taken in their capacities as directors and officers. We believe these provisions in our Certificate of Incorporation and our Bylaws and these indemnification agreements are necessary to attract and retain qualified persons as
directors and officers. 
 Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors,
officers, or control persons, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. 

Transfer Agent, Warrant Agent and Registrar 

The transfer agent, warrant agent and registrar for our units, common stock and warrants is Continental Stock Transfer & Trust
Company. 
 Listing of Securities 
 Our
units, common stock and public warrants are listed on The Nasdaq Capital Market under the symbols “VINCU,” “VINC” and “VINCW,” respectively. 

  
 5EX-10.7

 Exhibit 10.7 

EXECUTIVE EMPLOYMENT AGREEMENT 

This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), dated as of December 23, 2020, is by and between Vincera Pharma,
Inc., a Delaware corporation (the “Company”), and Hermes Garban (“Executive”). 
 WHEREAS, the Company
wishes to retain the services of Executive and Executive wishes to be employed by the Company on the terms and subject to the conditions set forth in this Agreement. 

NOW THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, and the respective covenants, agreements
and undertakings set forth herein, the Company and Executive agree as follows: 
 1. Employment.  

(a) Effective Date. Your employment will commence on March 1, 2020 (“Effective Date”). 

(b) Title; Duties. Executive shall serve as the Chief Medical Officer of the Company and shall have such authority and responsibilities,
and perform such duties, as may be consistent with such title and position as may be determined and assigned by the Chief Executive Officer of the Company (the “CEO”). 

(c) Time and Effort. Executive agrees to devote substantially all of his normal business efforts and time during normal business hours
to the performance of Executive’s duties hereunder and such other duties consistent with such title and position as may reasonably be determined and assigned by the CEO. During the term of this Agreement, Executive shall not engage in any other
employment, occupation, consulting or other business activity that competes with the business of the Company or engage in any other activities that conflict or interfere with Executive’s obligations under this Agreement. 

(d) Term. The term of this Agreement shall commence on the Effective Date and shall continue until terminated by either party as
provided in Section 5 hereof. 
 2. Compensation; Benefits. 

(a) Base Salary. Executive shall be paid an annual base salary of $390,000 (the “Base Salary”), payable in accordance
with the Company’s standard payroll practices. Executive’s Base Salary shall be reviewed by the Board of Directors of the Company (the “Board”) periodically (but no less than annually) for possible increase (but not
decrease) in light of Executive’s performance, external market conditions, the Company’s financial condition and performance and such other factors as the Board deems appropriate. If Executive’s Base Salary is increased from time to
time, the most recent higher level shall be deemed to be the Base Salary from that point until otherwise increased (but not decreased). 
  

 (b) Bonus Plans. Executive shall be entitled to participate in the Company’s
annual performance bonus plan at a level appropriate for the position and duties of Executive and subject to the terms and conditions established by the Board for such bonus plan. Bonuses will be paid annually based on both the success of the
Company in meeting its goals and Executive’s individual performance. Executive’s annual target performance bonus will be equal to thirty percent (30%) of the then applicable Base Salary, subject to increase (but not decrease) in light of
Executive’s performance, external market conditions, the Company’s financial condition and performance and such other factors as the Board deems appropriate. Except as otherwise provided in this Agreement, Executive must be employed by the
Company through the last day of the period to which the bonus relates and on the date on which bonuses are paid in order to be eligible to receive a bonus. Executive shall be entitled to participate in such other bonus plans as may be established by
the Company from time to time for executives of the Company at a level appropriate for the position and duties of Executive. The determination whether to establish, amend or discontinue, and the terms and conditions of, any Company bonus plans shall
be within the sole discretion of the Board. 
 (c) Equity Awards. Subject to approval by the Board, Executive shall be granted the
following equity awards under the Company’s 2020 Stock Incentive Plan (the “Plan”): 
 (i) Executive shall be granted
an incentive or non-statutory stock option (the “Option”), as determined by the Board, to purchase 150,000 shares of the Company’s Common Stock (the “Common Stock”). The
exercise price of the Option shall be the fair market value of the Common Stock on the date of grant as determined by the Board. If approved by the Board, the Option shall begin vesting on the Effective Date and, subject to Executive’s
continued employment, shall vest over a 36 month period following the Effective Date, with 1/3rd of the underlying shares vesting 12 months following the Effective Date and 1/36th of the underlying shares vesting on each monthly anniversary of the
Effective Date thereafter. The Option shall be granted under, and shall be subject to the terms and conditions of, the Plan and Executive’s individual Stock Option Agreement. 

(ii) In addition to the Option, Executive shall be granted a restricted stock unit (an “RSU”) representing the right to
receive up to 8,500 shares of the Common Stock. If approved by the Board, subject to Executive’s continued employment, the RSU will vest based and contingent upon the achievement of the Earnouts and issuance of the Earnout Shares (as such terms
are defined in the Merger Agreement, dated as of September 25, 2020, among LifeSci Acquisition Corp., LifeSci Acquisition Merger Sub, Inc., Vincera Pharma, Inc. and the stockholders’ representative)), as more fully described in your
individual Restricted Stock Unit Agreement.. The RSU shall be granted under, and shall be subject to the terms and conditions of, the Plan and Executive’s individual Restricted Stock Unit Agreement. 

(d) Vacation. Executive shall be entitled to annual paid vacation time of four (4) weeks, to be taken at such time or times as
Executive may select, consistent with his obligations hereunder. 

  
 2 

 (e) Other Employee Benefits. Executive shall be entitled to participate in any
Company-sponsored benefit plans and programs sponsored by the Company, including medical, dental, life and disability insurance, holidays and other perquisites, at a level appropriate for Executive’s position and duties and to the extent that
the Company makes such benefits generally available to executives of the Company. Executive’s eligibility to receive such benefits shall be subject in each case to the generally applicable terms and conditions for the benefits in question. The
Company may from time to time, in its sole discretion, amend, adjust or discontinue the benefits available to the Company’s executives and employees. 

(f) Business Expenses. The Company shall reimburse Executive for all reasonable and customary expenses incurred by Executive in
connection with the performance of Executive’s duties hereunder, all in accordance with the Company’s expense reimbursement policy as in effect from time to time. Such reimbursement shall be paid promptly following Executive’s
satisfaction of the requirements for expense reimbursement under the Company’s expense reimbursement policy but in no event later than the end of the calendar month following the calendar month in which satisfaction of such requirements
occurred. 
 (g) Withholding, Taxes, Etc. All forms of compensation payable pursuant to this Agreement shall be subject to reduction
to reflect applicable withholding and payroll taxes and all other deductions required by law. 
 3. Proprietary Information and Inventions
Agreement. As a condition of Executive’s employment, Executive shall be required to sign and comply with the Proprietary Information and Inventions Agreement attached hereto as Exhibit A (the “PIIA”), which requires,
among other things, the assignment of rights to any inventions made during Executive’s employment and non-disclosure of confidential information. 

4. Indemnification; D&O Insurance. Executive shall be entitled to indemnification, advancement of expenses and limitation of
liability to the fullest extent permitted by law and on terms no less favorable than those provided to other officers and directors of the Company, including entering into any form of indemnification or similar agreement providing for such rights
that is entered into with other officers and directors of the Company. In addition, the Company shall obtain and maintain a director and officer insurance policy with coverage and other terms comparable to those for similar companies in the industry
and take such action as may be necessary to ensure that Executive is covered by such policy for acts or omissions occurring during his employment. 

5. At-Will Employment; Termination of Employment.  

(a) At-Will Employment. Executive’s employment with the Company under this Agreement is
employment “at-will.” Executive may terminate his employment with the Company at any time and for any reason whatsoever (or no reason) simply by providing written notice to the Company. Likewise, the
Company may terminate Executive’s employment at any time, upon sixty (60) days’ written notice to Executive. 

  
 3 

 (b) Termination for Cause or as a Result of Death, Disability or Resignation without Good
Reason. If Executive’s employment is terminated by the Company for Cause (as defined below), or as a result of death or Disability (as defined below) or the resignation by Executive without Good Reason (as defined below), the Company shall
pay Executive (i) unpaid Base Salary accrued up to the date of termination, (ii) accrued but unused vacation, (iii) benefits payable to Executive pursuant to the terms and conditions of any benefit plan or program in which Executive
participated during the term of his employment, the right to which was vested on the date of his termination under the terms and conditions of such plans and programs, and (iv) unreimbursed business expenses (collectively, the “Accrued
Compensation”). Payment of the Accrued Compensation shall be made upon the date of termination, except as may otherwise be provided under the terms of any applicable benefit plan or program. 

(c) Termination without Cause or Resignation for Good Reason. If Executive’s employment is terminated by the Company without Cause
or Executive resigns for Good Reason, the Company shall pay Executive the Accrued Compensation and shall provide the additional payments and benefits set forth in this Section 5(c). As a condition to such additional payments and benefits,
Executive must execute a full release of claims in a form satisfactory to the Company (the “Release”), which Release shall not be revoked and shall become fully effective and irrevocable within sixty (60) days of
Executive’s termination, or such earlier deadline required by the Release (such deadline, the “Release Deadline”). 

(i) The Company shall pay to Executive, on the Release Deadline, a lump sum amount (less applicable payroll deductions) equal to (A) one
(1) times his then current Base Salary, and (B) one (1) times his then current target bonus for the fiscal year in which such termination occurred as if the Company and Executive had fully achieved all applicable performance goals at their
target level and remained employed through the date necessary to receive and fully earn payment of such bonus. 
 (ii) The vesting of all
outstanding stock options, restricted stock units, restricted stock or other compensation based equity awards then held by Executive (the “Equity Awards”) that are subject to time-based vesting shall be accelerated so that the
number of shares vested under such Equity Awards shall equal that number of shares that would have been vested if Executive had continued to render employment services to the Company for a period of twelve (12) continuous months following the
date of Executive’s termination. The vesting of Equity Awards that are subject to performance-based vesting shall accelerate only to the extent provided in the applicable award agreement. In addition, the period following such termination in
which vested stock options or similar Equity Awards may be exercised shall be not be less than three (3) months following such termination. 

(iii) Until the earlier of six (6) months following the date of termination or the date Executive becomes eligible for group health
insurance coverage through a new employer, if Executive elects to continue health insurance coverage under the Consolidated Budget Reconciliation Act of 1985, as amended (“COBRA”), then so long as Executive is paying COBRA premiums,
and beginning in the month following Executive’s termination (or, if later, the Release Deadline, with a catch-up payment for payments deferred pending the Release Deadline), the Company shall pay
Executive a monthly payment equal to the amount that was paid by the Company for such coverage as of the date of termination and any increases in such premiums during such period that may be required to maintain the same level of coverage. Executive
shall be responsible for filing any necessary paperwork for COBRA coverage, paying all premiums and providing the Company with appropriate evidence of such premium payments. 

  
 4 

 (d) Impact of Change in Control. 

(i) If Executive’s employment is terminated by the Company without Cause or Executive resigns for Good Reason within three months prior
to, or within 12 months following, the consummation of a Change in Control of the Company, Executive shall be entitled to receive the Accrued Compensation and the additional payments and benefits set forth in Section 5(c) hereof on the same
terms and conditions, including the execution and effectiveness of the Release by the Release Deadline, provided that all Equity Awards subject to time-based vesting then held by Executive shall vest with respect to 100% of the shares underlying
such Equity Awards with such additional acceleration effective on the Release Deadline following the later of such termination or the consummation of the Change in Control. 

(ii) In the event that the payments and other benefits provided for in this Agreement or otherwise payable to Executive constitute
“parachute payments” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”) and would be subject to the excise tax imposed by Section 4999 of the Code (the
“Excise Tax”), Executive’s payments and benefits under this Agreement shall be either (A) delivered in full or (B) delivered as to such lesser extent as would result in no portion of such payments and benefits being
subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax, results in the receipt by Executive on an after-tax
basis of the greatest amount of payments and benefits, notwithstanding that all or some portion of such payments and benefits may be taxable under Section 4999 of the Code. 

(iii) Unless the Company and Executive otherwise agree in writing, any determination required under subsection (ii) above shall be made
in writing by the Company’s independent public accountants (the “Accountants”), whose determination shall be conclusive and binding upon Executive and the Company for all purposes. For purposes of making the calculations
required by this Section 5(d)(iii), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of
the Code. The Company and Executive shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make such determination. The Company shall bear all costs the Accountants may reasonably incur
in connection with any calculations contemplated by this Section 5(d)(iii). Any reduction in payments or benefits required by this Section 5(d)(iii) shall occur in a manner necessary to provide Executive with the greatest economic benefit.
If more than one manner of reduction of payments or benefits yields the greatest economic benefit, the payments and benefits shall be reduced pro rata, provided that the reduction shall be applied first to any payments or benefits that are not
subject to Section 409A and then shall be applied to payments or benefits (if any) that are subject to Section 409A, with the payments or benefits payable latest in time subject to reduction first. To the extent required to avoid a
violation of Section 409A of the Code, in no event shall the Company or Executive exercise any discretion with respect to the ordering of any reduction of payments or benefits pursuant to this Section 5(d)(iii). 

  
 5 

 (e) Definitions. For purposes of this Agreement: 

(i) “Cause” shall mean the good faith determination by the Board that one of the following events has occurred following the
Effective Date: (A) conviction of, or plea of nolo contendere to, any felony or crime of moral turpitude; (B) act of fraud, theft or embezzlement with respect to the Company; (C) willful failure to substantially perform his
duties or comply with lawful Company policies or Board instructions (other than as a result of Executive’s mental or physical disability) that causes material harm to the Company (after written notice thereof and a reasonable opportunity to
remedy such failure); (D) willful breach of fiduciary duty that causes material harm to the Company; or (E) willful and material breach of this Agreement or the PIIA (after written notice thereof and a reasonable opportunity to remedy such
breach). 
 (ii) “Change in Control” shall be as defined in the Plan. 

(iii) “Disability” shall mean the inability of Executive, with reasonable accommodation, to perform the essential functions
of Executive’s position and duties for at least 180 consecutive days. 
 (iv) “Good Reason” shall mean any action by
the Company (or its successors or acquirers) that, without the written consent of Executive, results in any of the following, provided that Executive provides notice to the Company within ninety (90) days of the initial occurrence of any such
action, such action is not cured by the Company within thirty (30) days of such notice and Executive resigns within sixty (60) days following expiration of the cure period: (A) a material diminishment in Executive’s title,
authority, duties or responsibilities (other than a mere change in title following a Change in Control to a substantially similar position with a successor or acquirer); (B) a material reduction in Executive’s base compensation or target bonus;
(C) a material reduction in Executive’s participation in bonus, incentive or other benefit plans or programs or other action that materially and adversely affects Executive’s working conditions, in each case in a manner that affects
Executive disproportionately to that of other comparable executives; (D) following a Change in Control, a change in the principal work site of Executive by more than fifty (50) miles; (E) a material breach by the Company of the terms of
this Agreement or any Equity Award agreement after written notice thereof and a reasonable opportunity to remedy such breach; or (F) the failure of any successor or acquirer of the Company to assume the Company’s obligations under this
Agreement. 
 (f) Section 409A. 

(i) Payments and benefits under this Agreement are intended to be exempt from the definition of “nonqualified deferred compensation”
under Section 409A of the Code and the regulations promulgated thereunder (“Section 409A”) to the maximum extent possible. If any payments or benefits under this Agreement are or become subject to
Section 409A, the relevant provisions of this Agreement are intended to comply with the applicable requirements of Section 409A with respect to such payments or benefits and shall be interpreted and administered consistent with this
intent. 

  
 6 

 (ii) Each payment under this Agreement that is made in a series of scheduled installments
shall be deemed a separate payment for purposes of Section 409A. Executive’s date of termination for purposes of determining the date that any payment or benefit is to be paid under this Agreement, and for purposes of determining whether
Executive is a “Specified Employee” (within the meaning of Section 409A, as determined by the Company) on the date of termination, shall be the date on which Executive has incurred a “separation from service” within
the meaning of Section 409A. If any payment or benefit provided pursuant to this Agreement provides for a “deferral of compensation” within the meaning of Section 409A, (A) the amount of the payment or benefit provided
thereunder in any given calendar year shall not affect the amount of such payment or benefit provided in any other calendar year (except that a plan providing medical or health benefits may impose a generally applicable limit on the amount that may
be reimbursed or paid), (B) any portion of such payment or benefit provided in the form of a reimbursement shall be paid to Executive on or before the last day of the calendar year following the calendar year in which the expense was incurred, and
(C) such payment or benefit shall not be subject to liquidation or exchange for any other benefit. 
 (iii) Notwithstanding anything in
this Agreement or elsewhere to the contrary, if the Company is a public company on the date of Executive’s termination and Executive is a Specified Employee” (as determined by the Company) on such termination date, and the Company
reasonably determines that any payment or benefit under this Agreement on account of such separation from service, constitutes nonqualified deferred compensation that will subject Executive to “additional tax” under
Section 409A(a)(1)(B) of the Code (together with any interest or penalties imposed with respect to, or in connection with, such tax, a “409A Tax”) with respect to the payment of such amount or the provision of such benefit if
paid or provided at the time specified in the Agreement, then the payment or provision thereof shall be made (without interest) on the first business day of the seventh month following the date of termination or, if earlier, the date of
Executive’s death (the “Delayed Payment Date”). The Company and Executive may agree to take other actions to avoid the imposition of a 409A Tax at such time and in such manner as permitted under Section 409A. In the
event that this section requires a delay of any payment, such payment shall be accumulated and paid in a single lump sum (without interest) on the Delayed Payment Date. 

6. Miscellaneous. 
 (a)
Governing Law. This Agreement and the resolution of any dispute arising out of, related to, or in any way connected with, this Agreement, Executive’s employment with the Company or the termination of such employment shall be governed by
the laws of the State of California, excluding its conflict of laws rules to the extent such rules would apply the law of another jurisdiction. To the extent not subject to arbitration as described below, the parties consent to the jurisdiction of
all federal and state courts in California, and agree that venue shall lie exclusively in Santa Clara County, California. If any party brings any suit, action, counterclaim or arbitration to enforce or interpret the provisions of this Agreement, the
prevailing party therein shall be entitled to recover a reasonable allowance for attorneys’ fees and litigation expenses in addition to court or arbitration costs. 

  
 7 

 (b) Arbitration. The Company believes that arbitration is the most fair and efficient
way to resolve workplace disputes. It is therefore a condition to Executive’s employment that Executive execute and deliver to the Company the Agreement to Arbitrate (“Arbitration Agreement”), in the form attached hereto
as Exhibit B. As more fully set forth in the Arbitration Agreement, by signing the Arbitration Agreement, both the Company and Executive agree that, to the fullest extent permitted by law and except as otherwise noted in the Arbitration
Agreement, any and all disputes relating in any way to this Agreement, Executive’s employment with the Company or the termination of such employment shall be submitted exclusively to final and binding individual arbitration. 

(c) Assignment. This Agreement and all rights hereunder shall be binding upon and inure to the benefit of and be enforceable by the
parties hereto and their respective personal or legal representatives, executors, administrators, heirs, distributees, devisees, legatees, successors and permitted assigns. This Agreement is personal in nature, and neither of the parties to this
Agreement shall, without the written consent of the other, assign or transfer this Agreement or any right or obligation under this Agreement to any other person or entity; provided, however, that the Company may assign this Agreement without the
consent of Executive in connection with any merger, consolidation or other sale or transfer of substantially all of its assets or business provided that the assignee or
successor-in-interest to the Company assumes all obligations of the Company under this Agreement. If Executive should die while any amounts are still payable to
Executive as provided in this Agreement, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to Executive’s designated beneficiary or, if there be no such designee, to
Executive’s estate. 
 (d) Notices. All notices provided for or permitted to be given pursuant to this Agreement must be in
writing. All notices shall be given to the other party by personal delivery, overnight courier (with receipt signature) or facsimile or email transmission (with confirmation of transmission) to the Company or Executive at the Company’s
principal executive offices if to the Company or to the residential address of Executive as contained in Executive’s personnel file if to Executive. Each such notice shall be deemed effective upon the date of actual receipt in the case of
personal delivery, receipt signature in the case of overnight courier or confirmation of transmission in the case of facsimile or email. 

(e) Severability. In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be
illegal, unenforceable, or void, this Agreement shall continue in full force and effect without such provision. The remainder of this Agreement shall be interpreted so as best to effect the intent of the Company and Executive, and the parties shall
use their best efforts to find an alternative way to achieve the same result. 
 (f) Integration. This Agreement represents the entire
agreement and understanding between the parties as to the subject matter herein and supersedes, merges and voids all prior or contemporaneous agreements with respect to such subject matter, whether written or oral. 

(g) Amendments and Waivers. No amendment, modification or waiver of any of the provisions of this Agreement shall be binding unless in
writing and signed by Executive and by an authorized officer of the Company (other than Executive). No waiver by either party of any provision of this Agreement by the other party will be considered a waiver of any other provision or of the same
provision at another time. 

  
 8 

 (h) Counterparts. This Agreement may be executed in counterparts, and each
counterpart shall have the same force and effect as an original and shall constitute an effective, binding agreement on the part of each of the undersigned. 

IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, as of the day
and year first above written. 
 [signatures on following page] 

  
 9 

			
	VINCERA PHARMA, INC.
		
	By	 	 /s/ Ahmed Hamdy, MD

		 	Ahmed Hamdy, MD
		 	Chairman, President and Chief Executive Officer
	
	EXECUTIVE
	
	 /s/ Hermes Garban

	Hermes Garban

  
 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]